



## Phlecs receives a new grant from EIT Health to start sales in Germany

High Tech Campus Eindhoven, the Netherlands

June 7, 2022

Dutch MedTech start-up Phlecs has just been selected by EIT Health to participate in its Bridgehead Europe programme 2022.

See EIT Health's press release: <https://eithealth.eu/news-article/29-start-ups-selected-for-bridgehead-2022/>

Twenty-nine scale-ups developing diverse healthcare technologies have been selected to participate in the Bridgehead programme. Among them is Phlecs, the Dutch start-up that addresses unmet needs in dermatology with UV-free phototherapy solutions.

Itching is highly prevalent among the older adults. Studies in the Netherlands and in Denmark show that up to 50% of nursing home residents suffer from Chronic Itching. It affects also children, the 10 to 20% of those who are diagnosed with eczema.

Current treatments have important limitations, because of overmedication, potential side effects and the time it requires to provide skin care. Because of that, adherence to treatments is low and this significantly impacts the quality of life of our children, parents, and grandparents.

Phlecs is only 3 years old but leverages more than 15 years of clinical research and technology development originated at Philips. In particular, studies show that blue light, that is UV-free so easy and safe to administrate at home, **is effective to reduce itching, hypertension and depression**. These clinical results are confirmed with the most recent studies conducted at the Universities of Lodz in Poland and Düsseldorf in Germany using the Full Body Blue Light device developed by Phlecs.

David Aubert, Phlecs CEO and Co-founder comments: *"With this new grant from EIT Health, Phlecs will accelerate the commercialization of the Full Body Blue Light device in Germany. We want to reach early adopters such as medical universities that want to further research on blue light therapy, rehabilitation centers that want to offer a UV-free treatment to their patients and nursing homes that have a special interest with innovation."*

## About EIT Health

EIT Health's Bridgehead programme brings together European health entrepreneurs who want to grow their business beyond their home market with the world's top incubators and accelerators who have the expertise and resources to make it happen. The Bridgehead programme helps match scale-up's with an incubator or accelerator from EIT Health's approved network. Together, they will plan how to access new markets quickly and decisively, tap into local networks of partners and clients, access infrastructure and understand new regulatory systems. The scale-up's are given the seasoned expertise, insight and support needed to help realize their business ambitions.

For more information: <https://eithealth.eu/programmes/bridgehead/>

## About Phlecs

Phlecs is a Dutch start-up founded by 4 former PHILIPS employees with many years of experience in photo-dermatology. Over the last 15 years extensive clinical research has been conducted on photo-dermatology treatments using UV-free LED lighting. Many studies (<https://www.phlecs.com/clinical-studies/>) have been published that show the efficacy of blue light therapy for the treatment of skin diseases such as Psoriasis, Eczema or itching. New studies, not yet published, confirm the safety and effectiveness of blue light therapy for the treatment of inflammatory skin diseases such as elderly itching. The Phlecs Full Body Blue Research device that has been introduced last year after obtaining the medical CE certification. The device is currently used by dermatology clinics to do research on blue light and will be used in large nursing homes that have the facility to provide the treatment. Phlecs has initiated the development of a Full Body Home connected device that brings therapy at patient's bed with 2 patent filings this year. This device will be launched in 2025, sold to care homes and home care service providers.

For more information: <https://www.phlecs.com>  
[david.aubert@phlecs.com](mailto:david.aubert@phlecs.com)